- Summary
- Guest(s)
- Company(s)
Fintan Walton talks to Rob Wills, VP Alliance Management, Pharmaceuticals Group, Johnson & Johnson, about the development of the Alliance Management group since its establishment in 2001. Rob outlines the need for superior capabilities in this area of the business in order to cope with increases in deal complexity in recent years.
They ask the important question ‘What isn't alliance management?' and discuss the use of metrics for determining alliance success. Rob also outlines the expectations that Johnson & Johnson have from potential partners in terms of committing resources to the alliance management process and reveals what triggers the alliance management team to become involved in the negotiation process.
Rob Wills
VP Alliance Management
Pharmaceuticals Group, Johnson & Johnson
Johnson & Johnson Research (JJR), located in the Australian Technology Park in Sydney, is part of the Johnson & Johnson (J&J) family of companies. The decentralised structure of J&J means that the organisation is a family of 200 operating companies, with more than US$4.68 B invested in research and development. It is a R&D global partner of choice. JJR provides important strategic and competitive advantages for J&J in the Asia Pacific and also more broadly internationally. The company has established a world leadership position in cell and gene therapy, which it underpins with its molecular diagnostic platforms and discovery research on RNA and DNA products. JJR’s additional research area - natural product chemistries - is providing novel structures with bioactivities in disease areas of significant interest.